Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.

Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, André AK, Wang Q, Carr RA, Ratain MJ. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.

View in: PubMed